Home > Press Releases > Pharmacogenomics Market

Pharmacogenomics Market Likely to Surpass ~USD 13 billion by 2035

Report Code: HC-45357  |  Published in: Mar 2026, By MarketGenics  |  Number of pages: 283
Get PDF
Buy

Global Pharmacogenomics Market Forecast 2035:

According to the report, the global pharmacogenomics market is likely to grow from USD 4.9 Billion in 2025 to USD 13.1 Billion in 2035 at a highest CAGR of 10.4% during the time period. The global pharmacogenomics market is becoming increasingly popular and growing strongly because of the increased use of personalized medicine, the increased incidence of chronic and complex diseases, and the need to improve drug efficacy and reduce adverse events.

Pharmacogenomic tests are being implemented rapidly in hospitals and research organizations to help providers create customized therapy for each patient based on their genetic profile in order to optimize treatment outcomes and/ or to enhance operational efficiency. Pharmaceutical companies are also implementing pharmacogenomic data during drug discovery to reduce the number of phase III failures and shorten the duration of clinical trial cycles.

Innovation is being driven by advances in Next-Generation Sequencing (NGS) technology to enable additional accuracy in interpretations of gene variants and increase the potential for pharmacogenomics to be applied across a wider range of therapeutic areas including oncology, cardiology, psychiatry and rare disease. Additionally, the expansion of direct-to-consumer pharmacogenomic testing is allowing patients to access information and insights for personalized therapy which creates opportunities for all stakeholders including other providers, diagnostics companies and genomic service providers.                                                                                      

Key Driver, Restraint, and Growth Opportunity Shaping the Global Pharmacogenomics Market

The global pharmacogenomics market experiences growth because hospitals and clinics increasingly use pharmacogenomic tests to enhance their processes for choosing medications and determining treatment dosages and monitoring patient progress. Healthcare facilities adopt pharmacogenomic testing because it provides essential genetic information which enables them to implement precision medicine for better patient results and decreased adverse drug effects and improved healthcare system performance.

However, the key obstacle to overcome Genetic variant interpretation becomes difficult because it requires understanding laws which differ between various population groups and needs specialized bioinformatics skills for Electronic Health Record systems but this restricts accessibility in small healthcare facilities and low-resource medical institutions.

Researchers consider pharmacogenomics to be a field with significant potential because it enables mental health professionals to use genetic testing to develop targeted treatments for antidepressants and antipsychotic medications. This application establishes customized treatment solutions which help medical professionals decrease their dependence on trial-and-error methods to discover patient-specific medications while it enables healthcare systems to implement precision medicine as a standard practice.

Impact of Global Tariff Policies on the Pharmacogenomics Market Growth and Strategy

Regulatory frameworks together with healthcare policies currently establish the primary guidelines which govern the worldwide pharmacogenomics market through their effects on testing practices and clinical research activities and drug development methods. North American and European and Asia Pacific healthcare providers together with pharmaceutical companies choose between various genomic testing platforms and service providers because they want to meet regulatory requirements while achieving optimal balance between testing expenses and result precision and healthcare effectiveness.

The increasing expenses associated with sequencing technologies together with bioinformatics tools and laboratory infrastructure have created reimbursement difficulties which lead providers to adopt pharmacogenomic testing only for critical therapeutic fields like oncology and cardiology and psychiatry while this choice affects when tests become available to patients.

National precision medicine programs receive support from both governments and health agencies throughout North America and Asia Pacific, which includes the U.S. All of Us Research Program and China National Genomics Project, to advance local genomic studies through enhanced testing access and development of local genomic study facilities, which will create a sustainable pharmacogenomics system that can operate under both financial and official restraints.

Expansion of Global Pharmacogenomics Market

Technological Innovation, Clinical Integration, and Government Initiatives Driving the Global Pharmacogenomics Market Expansion

  • The rapid advancement of technology within the pharmacogenomics market has been a driving force behind the global market, including developments in artificial intelligence‑enabled genomic interpretation platforms and cutting-edge sequencing technologies that enhance our ability to predict how people will respond to drugs and how we can best classify them for treatment.
  • Several healthcare organizations are infusing pharmacogenomic testing into their routine clinical practices and providing evidence of this through the activity of pilot programs utilizing PGx testing in both clinical departments and tertiary care settings to enhance the efficacy and quality of care provided via tailored treatment decisions based on individualized characteristics and responsiveness.
  • Additionally, government programs and financing such as the U.S. All of Us Research Programme and various national precision medicine initiatives being rolled out across Europe and Asia are establishing large repositories of genomic-related data and encouraging collaboration with researchers through the development of supportive policy frameworks which will support both clinical adoption as well as research collaboration by increasing accessibility and standardizing processes.
  • These multiple initiatives are rapidly converting the prevalent historical model of therapy into one of precision medicine, which continues to broaden the market potential of pharmacogenomics across all major therapeutic categories.

Regional Analysis of Global Pharmacogenomics Market

  • North America shows the highest level of adoption in pharmacogenomics market because its healthcare system delivers advanced services and its population has high rates of chronic and complex medical conditions and its insurance system provides extensive coverage and reimbursement options.
  • Additionally, the National Institutes of Health (NIH) reports that genomics-based therapies provide treatment advantages to a substantial number of U.S. cancer and cardiovascular and psychiatric patients which leads to increased pharmacogenomic testing use in clinical settings. North America maintains market leadership through its extensive investments in next-generation sequencing technologies and AI-powered genomic analysis systems and extensive precision medicine programs like the All of US Research Program.
  • The Asia Pacific region shows the fastest development in pharmacogenomics because its healthcare sector moves toward digital technology and people start to understand personalized medicine and genomic testing becomes more available to remote and disadvantaged communities. Countries such as India and China increasingly adopt mobile genetic testing platforms together with low-cost sequencing technologies.
  • Notably, India’s National Health Stack and precision medicine pilot programs offer genomic services to millions while domestic startups partner with global genomics companies to accelerate market entry. The combination of government backing and technological implementation and rising clinical knowledge creates conditions for Asia Pacific to become the fastest expanding region in global pharmacogenomics market.

Prominent players operating in global pharmacogenomics market include prominent companies such as Abbott Laboratories, Agilent Technologies, Inc., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., Novogene Co., Ltd., PacBio (Pacific Biosciences of California, Inc.), Personalis, Inc., QIAGEN N.V., Revvity, Inc., SOPHiA GENETICS SA, Takara Bio Inc., Thermo Fisher Scientific Inc., along with several other key players.

The global pharmacogenomics market has been segmented as follows:

Global Pharmacogenomics Market Analysis, by Product & Services

  • Kits and Reagents
  • Instruments
  • Software and Bioinformatics Platforms
  • Pharmacogenomic Testing Services
  • Data Analysis and Interpretation Services
  • Others

Global Pharmacogenomics Market Analysis, by Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray Technology
  • Gel Electrophoresis
  • Mass Spectrometry
  • DNA Sequencing Platforms
  • Others

Global Pharmacogenomics Market Analysis, by Therapeutic Area

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Pain Management
  • Metabolic Disorders
  • Psychiatric Disorders
  • Others

Global Pharmacogenomics Market Analysis, by Workflow Stage

  • Sample Preparation
  • Gene Sequencing and Genotyping
  • Variant Detection and Analysis
  • Data Interpretation and Clinical Reporting
  • Others

Global Pharmacogenomics Market Analysis, by Gene Type

  • Cytochrome P450 (CYP) Genes
  • Drug Transporter Genes
  • Drug Target Genes
  • Immune Response Genes
  • Others

Global Pharmacogenomics Market Analysis, by Indication

  • Cancer
  • Cardiovascular Disorders
  • Depression and Psychiatric Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Others

Global Pharmacogenomics Market Analysis, by Application

  • Drug Discovery and Development
  • Clinical Diagnostics
  • Personalized Medicine
  • Precision Medicine
  • Pharmacogenetic Testing
  • Biomarker Identification
  • Others

Global Pharmacogenomics Market Analysis, by End User

  • Hospitals and Clinics
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Diagnostic Laboratories
  • Others

Global Pharmacogenomics Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Natures
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Natures
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Pharmacogenomics Market Outlook
      • 2.1.1. Pharmacogenomics Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising adoption of personalized medicine to optimize drug efficacy and minimize adverse reactions.
        • 4.1.1.2. Technological advancements in next-generation sequencing and AI-driven genomic interpretation.
        • 4.1.1.3. Government-backed precision medicine initiatives and favorable reimbursement policies.
      • 4.1.2. Restraints
        • 4.1.2.1. High cost of pharmacogenomic testing and limited insurance coverage in some regions.
        • 4.1.2.2. Integration challenges with electronic health records and clinical decision-support systems.
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis/ Ecosystem Analysis
    • 4.5. Cost Structure Analysis
    • 4.6. Porter’s Five Forces Analysis
    • 4.7. PESTEL Analysis
    • 4.8. Global Pharmacogenomics Market Demand
      • 4.8.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.8.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
        • 4.8.2.1. Y-o-Y Growth Trends
        • 4.8.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Pharmacogenomics Market Analysis, by Product & Services
    • 6.1. Key Segment Analysis
    • 6.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Product & Services, 2021-2035
      • 6.2.1. Kits and Reagents
      • 6.2.2. Instruments
      • 6.2.3. Software and Bioinformatics Platforms
      • 6.2.4. Pharmacogenomic Testing Services
      • 6.2.5. Data Analysis and Interpretation Services
      • 6.2.6. Others
  • 7. Global Pharmacogenomics Market Analysis, by Technology
    • 7.1. Key Segment Analysis
    • 7.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
      • 7.2.1. Next-Generation Sequencing (NGS)
      • 7.2.2. Polymerase Chain Reaction (PCR)
      • 7.2.3. Microarray Technology
      • 7.2.4. Gel Electrophoresis
      • 7.2.5. Mass Spectrometry
      • 7.2.6. DNA Sequencing Platforms
      • 7.2.7. Others
  • 8. Global Pharmacogenomics Market Analysis, by Therapeutic Area
    • 8.1. Key Segment Analysis
    • 8.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
      • 8.2.1. Oncology
      • 8.2.2. Cardiovascular Diseases
      • 8.2.3. Neurological Disorders
      • 8.2.4. Infectious Diseases
      • 8.2.5. Pain Management
      • 8.2.6. Metabolic Disorders
      • 8.2.7. Psychiatric Disorders
      • 8.2.8. Others
  • 9. Global Pharmacogenomics Market Analysis, by Workflow Stage
    • 9.1. Key Segment Analysis
    • 9.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Workflow Stage, 2021-2035
      • 9.2.1. Sample Preparation
      • 9.2.2. Gene Sequencing and Genotyping
      • 9.2.3. Variant Detection and Analysis
      • 9.2.4. Data Interpretation and Clinical Reporting
      • 9.2.5. Others
  • 10. Global Pharmacogenomics Market Analysis, by Gene Type
    • 10.1. Key Segment Analysis
    • 10.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Gene Type, 2021-2035
      • 10.2.1. Cytochrome P450 (CYP) Genes
      • 10.2.2. Drug Transporter Genes
      • 10.2.3. Drug Target Genes
      • 10.2.4. Immune Response Genes
      • 10.2.5. Others
  • 11. Global Pharmacogenomics Market Analysis, by Indication
    • 11.1. Key Segment Analysis
    • 11.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Indication, 2021-2035
      • 11.2.1. Cancer
      • 11.2.2. Cardiovascular Disorders
      • 11.2.3. Depression and Psychiatric Disorders
      • 11.2.4. Neurological Disorders
      • 11.2.5. Infectious Diseases
      • 11.2.6. Others
  • 12. Global Pharmacogenomics Market Analysis, by Application
    • 12.1. Key Segment Analysis
    • 12.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
      • 12.2.1. Drug Discovery and Development
      • 12.2.2. Clinical Diagnostics
      • 12.2.3. Personalized Medicine
      • 12.2.4. Precision Medicine
      • 12.2.5. Pharmacogenetic Testing
      • 12.2.6. Biomarker Identification
      • 12.2.7. Others
  • 13. Global Pharmacogenomics Market Analysis, by End User
    • 13.1. Key Segment Analysis
    • 13.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 13.2.1. Hospitals and Clinics
      • 13.2.2. Academic and Research Institutes
      • 13.2.3. Pharmaceutical and Biotechnology Companies
      • 13.2.4. Contract Research Organizations
      • 13.2.5. Diagnostic Laboratories
      • 13.2.6. Others
  • 14. Global Pharmacogenomics Market Analysis and Forecasts, by Region
    • 14.1. Key Findings
    • 14.2. Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 14.2.1. North America
      • 14.2.2. Europe
      • 14.2.3. Asia Pacific
      • 14.2.4. Middle East
      • 14.2.5. Africa
      • 14.2.6. South America
  • 15. North America Pharmacogenomics Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. North America Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Product & Services
      • 15.3.2. Technology
      • 15.3.3. Therapeutic Area
      • 15.3.4. Workflow Stage
      • 15.3.5. Gene Type
      • 15.3.6. Indication
      • 15.3.7. Application
      • 15.3.8. End User
      • 15.3.9. Country
        • 15.3.9.1. USA
        • 15.3.9.2. Canada
        • 15.3.9.3. Mexico
    • 15.4. USA Pharmacogenomics Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Product & Services
      • 15.4.3. Technology
      • 15.4.4. Therapeutic Area
      • 15.4.5. Workflow Stage
      • 15.4.6. Gene Type
      • 15.4.7. Indication
      • 15.4.8. Application
      • 15.4.9. End User
    • 15.5. Canada Pharmacogenomics Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Product & Services
      • 15.5.3. Technology
      • 15.5.4. Therapeutic Area
      • 15.5.5. Workflow Stage
      • 15.5.6. Gene Type
      • 15.5.7. Indication
      • 15.5.8. Application
      • 15.5.9. End User
    • 15.6. Mexico Pharmacogenomics Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Product & Services
      • 15.6.3. Technology
      • 15.6.4. Therapeutic Area
      • 15.6.5. Workflow Stage
      • 15.6.6. Gene Type
      • 15.6.7. Indication
      • 15.6.8. Application
      • 15.6.9. End User
  • 16. Europe Pharmacogenomics Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Europe Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Product & Services
      • 16.3.2. Technology
      • 16.3.3. Therapeutic Area
      • 16.3.4. Workflow Stage
      • 16.3.5. Gene Type
      • 16.3.6. Indication
      • 16.3.7. Application
      • 16.3.8. End User
      • 16.3.9. Country
        • 16.3.9.1. Germany
        • 16.3.9.2. United Kingdom
        • 16.3.9.3. France
        • 16.3.9.4. Italy
        • 16.3.9.5. Spain
        • 16.3.9.6. Netherlands
        • 16.3.9.7. Nordic Countries
        • 16.3.9.8. Poland
        • 16.3.9.9. Russia & CIS
        • 16.3.9.10. Rest of Europe
    • 16.4. Germany Pharmacogenomics Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Product & Services
      • 16.4.3. Technology
      • 16.4.4. Therapeutic Area
      • 16.4.5. Workflow Stage
      • 16.4.6. Gene Type
      • 16.4.7. Indication
      • 16.4.8. Application
      • 16.4.9. End User
    • 16.5. United Kingdom Pharmacogenomics Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Product & Services
      • 16.5.3. Technology
      • 16.5.4. Therapeutic Area
      • 16.5.5. Workflow Stage
      • 16.5.6. Gene Type
      • 16.5.7. Indication
      • 16.5.8. Application
      • 16.5.9. End User
    • 16.6. France Pharmacogenomics Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Product & Services
      • 16.6.3. Technology
      • 16.6.4. Therapeutic Area
      • 16.6.5. Workflow Stage
      • 16.6.6. Gene Type
      • 16.6.7. Indication
      • 16.6.8. Application
      • 16.6.9. End User
    • 16.7. Italy Pharmacogenomics Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Product & Services
      • 16.7.3. Technology
      • 16.7.4. Therapeutic Area
      • 16.7.5. Workflow Stage
      • 16.7.6. Gene Type
      • 16.7.7. Indication
      • 16.7.8. Application
      • 16.7.9. End User
    • 16.8. Spain Pharmacogenomics Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Product & Services
      • 16.8.3. Technology
      • 16.8.4. Therapeutic Area
      • 16.8.5. Workflow Stage
      • 16.8.6. Gene Type
      • 16.8.7. Indication
      • 16.8.8. Application
      • 16.8.9. End User
    • 16.9. Netherlands Pharmacogenomics Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Product & Services
      • 16.9.3. Technology
      • 16.9.4. Therapeutic Area
      • 16.9.5. Workflow Stage
      • 16.9.6. Gene Type
      • 16.9.7. Indication
      • 16.9.8. Application
      • 16.9.9. End User
    • 16.10. Nordic Countries Pharmacogenomics Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Product & Services
      • 16.10.3. Technology
      • 16.10.4. Therapeutic Area
      • 16.10.5. Workflow Stage
      • 16.10.6. Gene Type
      • 16.10.7. Indication
      • 16.10.8. Application
      • 16.10.9. End User
    • 16.11. Poland Pharmacogenomics Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Product & Services
      • 16.11.3. Technology
      • 16.11.4. Therapeutic Area
      • 16.11.5. Workflow Stage
      • 16.11.6. Gene Type
      • 16.11.7. Indication
      • 16.11.8. Application
      • 16.11.9. End User
    • 16.12. Russia & CIS Pharmacogenomics Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Product & Services
      • 16.12.3. Technology
      • 16.12.4. Therapeutic Area
      • 16.12.5. Workflow Stage
      • 16.12.6. Gene Type
      • 16.12.7. Indication
      • 16.12.8. Application
      • 16.12.9. End User
    • 16.13. Rest of Europe Pharmacogenomics Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Product & Services
      • 16.13.3. Technology
      • 16.13.4. Therapeutic Area
      • 16.13.5. Workflow Stage
      • 16.13.6. Gene Type
      • 16.13.7. Indication
      • 16.13.8. Application
      • 16.13.9. End User
  • 17. Asia Pacific Pharmacogenomics Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Asia Pacific Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Product & Services
      • 17.3.2. Technology
      • 17.3.3. Therapeutic Area
      • 17.3.4. Workflow Stage
      • 17.3.5. Gene Type
      • 17.3.6. Indication
      • 17.3.7. Application
      • 17.3.8. End User
      • 17.3.9. Country
        • 17.3.9.1. China
        • 17.3.9.2. India
        • 17.3.9.3. Japan
        • 17.3.9.4. South Korea
        • 17.3.9.5. Australia and New Zealand
        • 17.3.9.6. Indonesia
        • 17.3.9.7. Malaysia
        • 17.3.9.8. Thailand
        • 17.3.9.9. Vietnam
        • 17.3.9.10. Rest of Asia Pacific
    • 17.4. China Pharmacogenomics Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Product & Services
      • 17.4.3. Technology
      • 17.4.4. Therapeutic Area
      • 17.4.5. Workflow Stage
      • 17.4.6. Gene Type
      • 17.4.7. Indication
      • 17.4.8. Application
      • 17.4.9. End User
    • 17.5. India Pharmacogenomics Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Product & Services
      • 17.5.3. Technology
      • 17.5.4. Therapeutic Area
      • 17.5.5. Workflow Stage
      • 17.5.6. Gene Type
      • 17.5.7. Indication
      • 17.5.8. Application
      • 17.5.9. End User
    • 17.6. Japan Pharmacogenomics Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Product & Services
      • 17.6.3. Technology
      • 17.6.4. Therapeutic Area
      • 17.6.5. Workflow Stage
      • 17.6.6. Gene Type
      • 17.6.7. Indication
      • 17.6.8. Application
      • 17.6.9. End User
    • 17.7. South Korea Pharmacogenomics Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Product & Services
      • 17.7.3. Technology
      • 17.7.4. Therapeutic Area
      • 17.7.5. Workflow Stage
      • 17.7.6. Gene Type
      • 17.7.7. Indication
      • 17.7.8. Application
      • 17.7.9. End User
    • 17.8. Australia and New Zealand Pharmacogenomics Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Product & Services
      • 17.8.3. Technology
      • 17.8.4. Therapeutic Area
      • 17.8.5. Workflow Stage
      • 17.8.6. Gene Type
      • 17.8.7. Indication
      • 17.8.8. Application
      • 17.8.9. End User
    • 17.9. Indonesia Pharmacogenomics Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Product & Services
      • 17.9.3. Technology
      • 17.9.4. Therapeutic Area
      • 17.9.5. Workflow Stage
      • 17.9.6. Gene Type
      • 17.9.7. Indication
      • 17.9.8. Application
      • 17.9.9. End User
    • 17.10. Malaysia Pharmacogenomics Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Product & Services
      • 17.10.3. Technology
      • 17.10.4. Therapeutic Area
      • 17.10.5. Workflow Stage
      • 17.10.6. Gene Type
      • 17.10.7. Indication
      • 17.10.8. Application
      • 17.10.9. End User
    • 17.11. Thailand Pharmacogenomics Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Product & Services
      • 17.11.3. Technology
      • 17.11.4. Therapeutic Area
      • 17.11.5. Workflow Stage
      • 17.11.6. Gene Type
      • 17.11.7. Indication
      • 17.11.8. Application
      • 17.11.9. End User
    • 17.12. Vietnam Pharmacogenomics Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Product & Services
      • 17.12.3. Technology
      • 17.12.4. Therapeutic Area
      • 17.12.5. Workflow Stage
      • 17.12.6. Gene Type
      • 17.12.7. Indication
      • 17.12.8. Application
      • 17.12.9. End User
    • 17.13. Rest of Asia Pacific Pharmacogenomics Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Product & Services
      • 17.13.3. Technology
      • 17.13.4. Therapeutic Area
      • 17.13.5. Workflow Stage
      • 17.13.6. Gene Type
      • 17.13.7. Indication
      • 17.13.8. Application
      • 17.13.9. End User
  • 18. Middle East Pharmacogenomics Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Middle East Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Product & Services
      • 18.3.2. Technology
      • 18.3.3. Therapeutic Area
      • 18.3.4. Workflow Stage
      • 18.3.5. Gene Type
      • 18.3.6. Indication
      • 18.3.7. Application
      • 18.3.8. End User
      • 18.3.9. Country
        • 18.3.9.1. Turkey
        • 18.3.9.2. UAE
        • 18.3.9.3. Saudi Arabia
        • 18.3.9.4. Israel
        • 18.3.9.5. Rest of Middle East
    • 18.4. Turkey Pharmacogenomics Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Product & Services
      • 18.4.3. Technology
      • 18.4.4. Therapeutic Area
      • 18.4.5. Workflow Stage
      • 18.4.6. Gene Type
      • 18.4.7. Indication
      • 18.4.8. Application
      • 18.4.9. End User
    • 18.5. UAE Pharmacogenomics Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Product & Services
      • 18.5.3. Technology
      • 18.5.4. Therapeutic Area
      • 18.5.5. Workflow Stage
      • 18.5.6. Gene Type
      • 18.5.7. Indication
      • 18.5.8. Application
      • 18.5.9. End User
    • 18.6. Saudi Arabia Pharmacogenomics Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Product & Services
      • 18.6.3. Technology
      • 18.6.4. Therapeutic Area
      • 18.6.5. Workflow Stage
      • 18.6.6. Gene Type
      • 18.6.7. Indication
      • 18.6.8. Application
      • 18.6.9. End User
    • 18.7. Israel Pharmacogenomics Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Product & Services
      • 18.7.3. Technology
      • 18.7.4. Therapeutic Area
      • 18.7.5. Workflow Stage
      • 18.7.6. Gene Type
      • 18.7.7. Indication
      • 18.7.8. Application
      • 18.7.9. End User
    • 18.8. Rest of Middle East Pharmacogenomics Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Product & Services
      • 18.8.3. Technology
      • 18.8.4. Therapeutic Area
      • 18.8.5. Workflow Stage
      • 18.8.6. Gene Type
      • 18.8.7. Indication
      • 18.8.8. Application
      • 18.8.9. End User
  • 19. Africa Pharmacogenomics Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Africa Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Product & Services
      • 19.3.2. Technology
      • 19.3.3. Therapeutic Area
      • 19.3.4. Workflow Stage
      • 19.3.5. Gene Type
      • 19.3.6. Indication
      • 19.3.7. Application
      • 19.3.8. End User
      • 19.3.9. Country
        • 19.3.9.1. South Africa
        • 19.3.9.2. Egypt
        • 19.3.9.3. Nigeria
        • 19.3.9.4. Algeria
        • 19.3.9.5. Rest of Africa
    • 19.4. South Africa Pharmacogenomics Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Product & Services
      • 19.4.3. Technology
      • 19.4.4. Therapeutic Area
      • 19.4.5. Workflow Stage
      • 19.4.6. Gene Type
      • 19.4.7. Indication
      • 19.4.8. Application
      • 19.4.9. End User
    • 19.5. Egypt Pharmacogenomics Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Product & Services
      • 19.5.3. Technology
      • 19.5.4. Therapeutic Area
      • 19.5.5. Workflow Stage
      • 19.5.6. Gene Type
      • 19.5.7. Indication
      • 19.5.8. Application
      • 19.5.9. End User
    • 19.6. Nigeria Pharmacogenomics Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Product & Services
      • 19.6.3. Technology
      • 19.6.4. Therapeutic Area
      • 19.6.5. Workflow Stage
      • 19.6.6. Gene Type
      • 19.6.7. Indication
      • 19.6.8. Application
      • 19.6.9. End User
    • 19.7. Algeria Pharmacogenomics Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Product & Services
      • 19.7.3. Technology
      • 19.7.4. Therapeutic Area
      • 19.7.5. Workflow Stage
      • 19.7.6. Gene Type
      • 19.7.7. Indication
      • 19.7.8. Application
      • 19.7.9. End User
    • 19.8. Rest of Africa Pharmacogenomics Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Product & Services
      • 19.8.3. Technology
      • 19.8.4. Therapeutic Area
      • 19.8.5. Workflow Stage
      • 19.8.6. Gene Type
      • 19.8.7. Indication
      • 19.8.8. Application
      • 19.8.9. End User
  • 20. South America Pharmacogenomics Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. South America Pharmacogenomics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Product & Services
      • 20.3.2. Technology
      • 20.3.3. Therapeutic Area
      • 20.3.4. Workflow Stage
      • 20.3.5. Gene Type
      • 20.3.6. Indication
      • 20.3.7. Application
      • 20.3.8. End User
      • 20.3.9. Country
        • 20.3.9.1. Brazil
        • 20.3.9.2. Argentina
        • 20.3.9.3. Rest of South America
    • 20.4. Brazil Pharmacogenomics Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Product & Services
      • 20.4.3. Technology
      • 20.4.4. Therapeutic Area
      • 20.4.5. Workflow Stage
      • 20.4.6. Gene Type
      • 20.4.7. Indication
      • 20.4.8. Application
      • 20.4.9. End User
    • 20.5. Argentina Pharmacogenomics Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Product & Services
      • 20.5.3. Technology
      • 20.5.4. Therapeutic Area
      • 20.5.5. Workflow Stage
      • 20.5.6. Gene Type
      • 20.5.7. Indication
      • 20.5.8. Application
      • 20.5.9. End User
    • 20.6. Rest of South America Pharmacogenomics Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Product & Services
      • 20.6.3. Technology
      • 20.6.4. Therapeutic Area
      • 20.6.5. Workflow Stage
      • 20.6.6. Gene Type
      • 20.6.7. Indication
      • 20.6.8. Application
      • 20.6.9. End User
  • 21. Key Players/ Company Profile
    • 21.1. Abbott Laboratories
      • 21.1.1. Company Details/ Overview
      • 21.1.2. Company Financials
      • 21.1.3. Key Customers and Competitors
      • 21.1.4. Business/ Industry Portfolio
      • 21.1.5. Product Portfolio/ Specification Details
      • 21.1.6. Pricing Data
      • 21.1.7. Strategic Overview
      • 21.1.8. Recent Developments
    • 21.2. Agilent Technologies, Inc.
    • 21.3. BGI Genomics Co., Ltd.
    • 21.4. Bio-Rad Laboratories, Inc.
    • 21.5. Charles River Laboratories International, Inc.
    • 21.6. Danaher Corporation
    • 21.7. Eurofins Scientific SE
    • 21.8. F. Hoffmann-La Roche Ltd.
    • 21.9. Illumina, Inc.
    • 21.10. Laboratory Corporation of America Holdings
    • 21.11. Macrogen, Inc.
    • 21.12. Myriad Genetics, Inc.
    • 21.13. Novogene Co., Ltd.
    • 21.14. PacBio (Pacific Biosciences of California, Inc.)
    • 21.15. Personalis, Inc.
    • 21.16. QIAGEN N.V.
    • 21.17. Revvity, Inc.
    • 21.18. SOPHiA GENETICS SA
    • 21.19. Takara Bio Inc.
    • 21.20. Thermo Fisher Scientific Inc.
    • 21.21. Other Key Players

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation